Page 64 - Read Online

Page 154 Bibi et al. J Transl Genet Genom 2024;8:119-161 https://dx.doi.org/10.20517/jtgg.2023.50

92. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS. A dual-monoclonal sandwich assay for prostate-specific membrane
antigen: levels in tissues, seminal fluid and urine. Prostate 2000;43:150-7. PubMed
93. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of
prostate specific membrane antigen. Cancer 1998;83:2259-69. PubMed
94. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ
hybridization. Cancer Res 1997;57:2321-4. PubMed
95. Kuang Y, Weng X, Liu X, et al. Anti-tumor immune response induced by dendritic cells transduced with truncated PSMA IRES 4-
1BBL recombinant adenoviruses. Cancer Lett 2010;293:254-62. DOI
96. George DJ. An α-particle emitting antibody ([ Bi]J591) for radioimmunotherapy of prostate cancer. Prostate 2001;3:1. DOI
213
97. Fracasso G, Bellisola G, Cingarlini S, et al. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate
2002;53:9-23. DOI
98. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH. Radioimmunotherapy of prostate cancer in human
xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate
2004;58:145-55. DOI PubMed
99. Carroll PR. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen:
preclinical studies in nude mice bearing LNCaP human prostate tumor: Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D,
Goldsmith SJ, Bander NH, Division of nuclear medicine, department of radiology, New York presbyterian Hospital-Weill Medical
College of Cornell University, New York, NY. J Nucl Med 2003;44:610-617. Urol Oncol-Semin Origin Invest 2003;21:486-7. DOI
100. Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific
membrane antigen has potent anticancer activity. Prostate 2010;70:1286-94. DOI PubMed
101. Sartor O, Baghian A. Prostate specific membrane antigen binding radiopharmaceuticals: current data and new concepts. Front Med
2022;9:1060922. DOI PubMed PMC
102. Solin T, Kontturi M, Pohlmann R, Vihko P. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP):
evaluation by RNA blot analyses. Biochim Biophys Acta 1990;1048:72-7. DOI PubMed
103. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP. Tissue-specificity of prostate specific antigens: comparative analysis of
transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006;236:229-38. DOI PubMed
104. Graddis TJ, McMahan CJ, Tamman J, Page KJ, Trager JB. Prostatic acid phosphatase expression in human tissues. Int J Clin Exp
Pathol 2011;4:295-306. DOI PubMed PMC
105. Machlenkin A, Paz A, Bar Haim E, et al. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen
of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 2005;65:6435-42. DOI
106. Machlenkin A, Azriel-Rosenfeld R, Volovitz I, et al. Preventive and therapeutic vaccination with PAP-3, a novel human prostate
cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunol Immunother 2007;56:217-26. DOI
107. Olson BM, Frye TP, Johnson LE, et al. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol
Immunother 2010;59:943-53. DOI PubMed PMC
108. Spies E, Reichardt W, Alvarez G, Groettrup M, Ohlschläger P. An artificial PAP gene breaks self-tolerance and promotes tumor
regression in the TRAMP model for prostate carcinoma. Mol Ther 2012;20:555-64. DOI PubMed PMC
109. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med
2010;363:411-22. DOI
110. Kiessling A, Wehner R, Füssel S, Bachmann M, Wirth MP, Schmitz M. Tumor-associated antigens for specific immunotherapy of
prostate cancer. Cancers 2012;4:193-217. DOI PubMed PMC
111. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N
Engl J Med 2004;351:1502-12. DOI
112. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is
associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment
(IMPACT) trial. Urology 2013;81:1297-302. DOI PubMed
113. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med
2012;367:1187-97. DOI
114. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced
refractory prostate cancer. N Engl J Med 2004;351:1513-20. DOI
115. Sheikh NA, Petrylak D, Kantoff PW, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized
phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 2013;62:137-47. DOI PubMed
PMC
116. McNeel DG, Becker JT, Eickhoff JC, et al. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting
prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clin Cancer Res 2014;20:3692-704. DOI PubMed
PMC
117. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate
cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54. DOI PubMed
118. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med
2013;369:213-23. DOI